vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and NATIONAL BANKSHARES INC (NKSH). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $15.3M, roughly 1.1× NATIONAL BANKSHARES INC). NATIONAL BANKSHARES INC runs the higher net margin — 38.5% vs -7.8%, a 46.3% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 24.7%). Over the past eight quarters, NATIONAL BANKSHARES INC's revenue compounded faster (20.9% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
DERM vs NKSH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $15.3M |
| Net Profit | $-1.2M | $5.9M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 47.4% |
| Net Margin | -7.8% | 38.5% |
| Revenue YoY | 27.3% | 24.7% |
| Net Profit YoY | -182.0% | 91.0% |
| EPS (diluted) | $-0.04 | $0.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $15.3M | ||
| Q3 25 | $17.0M | $14.2M | ||
| Q2 25 | $15.0M | $13.3M | ||
| Q1 25 | $13.1M | $12.8M | ||
| Q4 24 | $12.6M | $12.2M | ||
| Q3 24 | $14.6M | $11.7M | ||
| Q2 24 | $14.9M | $10.9M | ||
| Q1 24 | $13.0M | $10.4M |
| Q4 25 | $-1.2M | $5.9M | ||
| Q3 25 | $-2.3M | $4.4M | ||
| Q2 25 | $-3.8M | $2.3M | ||
| Q1 25 | $-4.1M | $3.2M | ||
| Q4 24 | $1.5M | $3.1M | ||
| Q3 24 | $-2.4M | $2.7M | ||
| Q2 24 | $-3.4M | $-307.0K | ||
| Q1 24 | $-10.4M | $2.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 47.4% | ||
| Q3 25 | -9.0% | 37.9% | ||
| Q2 25 | -19.2% | 20.0% | ||
| Q1 25 | -25.3% | 30.5% | ||
| Q4 24 | 17.7% | 30.1% | ||
| Q3 24 | -19.8% | 27.5% | ||
| Q2 24 | -19.7% | -4.4% | ||
| Q1 24 | -77.4% | 25.8% |
| Q4 25 | -7.8% | 38.5% | ||
| Q3 25 | -13.6% | 31.1% | ||
| Q2 25 | -25.3% | 17.2% | ||
| Q1 25 | -31.0% | 25.3% | ||
| Q4 24 | 12.1% | 25.1% | ||
| Q3 24 | -16.3% | 22.8% | ||
| Q2 24 | -22.6% | -2.8% | ||
| Q1 24 | -80.1% | 20.8% |
| Q4 25 | $-0.04 | $0.93 | ||
| Q3 25 | $-0.09 | $0.69 | ||
| Q2 25 | $-0.16 | $0.36 | ||
| Q1 25 | $-0.18 | $0.51 | ||
| Q4 24 | $0.10 | $0.50 | ||
| Q3 24 | $-0.12 | $0.42 | ||
| Q2 24 | $-0.17 | $-0.05 | ||
| Q1 24 | $-0.53 | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $59.3M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $184.9M |
| Total Assets | $94.6M | $1.8B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $59.3M | ||
| Q3 25 | $24.9M | $42.3M | ||
| Q2 25 | $20.3M | $92.8M | ||
| Q1 25 | $21.1M | $122.5M | ||
| Q4 24 | $20.3M | $108.1M | ||
| Q3 24 | $22.5M | $49.8M | ||
| Q2 24 | $23.9M | $98.9M | ||
| Q1 24 | $24.1M | $121.2M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $184.9M | ||
| Q3 25 | $25.9M | $179.2M | ||
| Q2 25 | $19.2M | $168.7M | ||
| Q1 25 | $21.5M | $167.3M | ||
| Q4 24 | $20.1M | $156.4M | ||
| Q3 24 | $10.9M | $167.8M | ||
| Q2 24 | $11.3M | $149.0M | ||
| Q1 24 | $13.0M | $139.4M |
| Q4 25 | $94.6M | $1.8B | ||
| Q3 25 | $85.2M | $1.8B | ||
| Q2 25 | $81.2M | $1.8B | ||
| Q1 25 | $85.0M | $1.8B | ||
| Q4 24 | $80.2M | $1.8B | ||
| Q3 24 | $64.0M | $1.8B | ||
| Q2 24 | $65.2M | $1.8B | ||
| Q1 24 | $66.6M | $1.7B |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $17.9M |
| Free Cash FlowOCF − Capex | — | $15.2M |
| FCF MarginFCF / Revenue | — | 99.2% |
| Capex IntensityCapex / Revenue | — | 17.9% |
| Cash ConversionOCF / Net Profit | — | 3.04× |
| TTM Free Cash FlowTrailing 4 quarters | — | $23.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $17.9M | ||
| Q3 25 | $-2.4M | $6.1M | ||
| Q2 25 | $-942.0K | $2.1M | ||
| Q1 25 | $-2.8M | $2.6M | ||
| Q4 24 | $2.2M | $9.4M | ||
| Q3 24 | $-1.2M | $3.1M | ||
| Q2 24 | $-5.2M | $-3.0M | ||
| Q1 24 | $-5.0M | $3.8M |
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | — | $1.5M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $-4.0M | ||
| Q1 24 | — | $3.5M |
| Q4 25 | — | 99.2% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 11.5% | ||
| Q1 25 | — | 12.5% | ||
| Q4 24 | — | 50.5% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | -36.3% | ||
| Q1 24 | — | 33.8% |
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 9.3% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | — | 3.04× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | 1.46× | 3.07× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
NKSH
Segment breakdown not available.
